EXHIBIT 1

RIVOCERANIB (APATINIB)

Rivoceranib Pipeline

Clinical Program

Rivoceranib (Apatinib)

Rivoceranib (Apatinib) is the first successful small-molecule tyrosine kinase inhibitor to be approved in gastric cancer (China, Dec 2014). It is important to note that in the United States and other jurisdictions, Rivoceranib is investigational and safety and efficacy have not been established. Orphan Drug designation has been granted in the US, Europe and South Korea. It has been clinically tested with over 1,000 patients worldwide. Rivoceranib has also shown potential

elevar therapeutics

Home About Elevar Products News Contact Us



- Camrelizumab: anti-PD1 antibody (immunotherapy), Hengrui Pharm.
- TAS-102: cytotoxic drugs, Taiho Pharm (Lonsurf)
- Taxane: cytotoxic drugs, paclitaxel
- Nivolumab: anti-PD1 antibody (immunotherapy), BMS (Opdivo)

with chemotherapeutics and immunotherapy, as well as for maintenance therapy. Additional studies and research will need to be conducted to verify the clinical applications in this context.

For Patients

Rivoceranib is an oral anti-cancer compound being studied for its ability to fight solid cancers including late stage stomach cancer, colorectal cancer, liver cancer, and adenoid cystic carcinoma. Although rivoceranib is already approved and marketed in China, it is not yet approved for patients in the rest of the world. Therefore, safety and efficacy have not been established outside of China. Rivoceranib is being studied outside of China as an investigational drug. If you and your physician decide that a clinical trial may be the right option for you, you may contact the research staff listed in **clinicaltrials.gov** (search term apatinib or rivoceranib).

Clinical Trials

Elevar Therapeutics is currently conducting a global pivotal phase 3 trial of rivoceranib for patients with advanced or metastatic gastric cancer. The phase 3 trial is expected to enroll about 450 patients in 95 medical centers and 12 countries in Asia, North America, and Europe (**NCT#03042611**). The Company is also initiating studies with Rivoceranib in combination with immunotherapy.

Elevar Therapeutics has completed the phase 1/2a dose escalation and safety trial of rivoceranib. In this trial, rivoceranib demonstrated encouraging clinical benefit in study patients with advanced solid tumors, especially for

tolerated with rare incidence of grade 3/4 adverse events, with hypertension as the most significant adverse event.

Technical Description

Rivoceranib (Apatinib, YN968D1) is an orally bioavailable experimental drug candidate being developed outside of China by Elevar Therapeutics, for the treatment of solid tumors including advanced or metastatic gastric cancer, colorectal cancer, hepatocellular carcinoma, and adenoid cystic carcinoma. YN968D1 was first synthesized and patented by Advenchen Laboratories in Southern California. Apatinib is currently marketed in China for advanced gastric cancer by the Chinese-territory license-holder, Jiangsu Hengrui Medicine Co., Ltd under the brand name Aitan®. Elevar Therapeutics holds the global rights (excluding China) and has partnered for the development and marketing of rivoceranib in South Korea.

Rivoceranib is a selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumor-mediated angiogenesis. It has been clinically tested in over 1,000 patients worldwide. It has also shown potential to improve outcomes in combination with chemotherapeutics and immunotherapy, as well as for maintenance therapy. Additional studies and research will need to be conducted to verify the clinical applications in this context. It is important to note that in the United States, Rivoceranib is investigational and safety and efficacy have not been established.

Publications and Posters

- Updated Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer. **Connective Tissue Oncology Society (CTOS) Annual Meeting (2020)**.
- A phase 2 open-label, multicenter study to evaluate efficacy and safety of rivoceranib in recurrent or metastatic adenoid cystic carcinoma. **ASCO Annual Meeting (2020)**.
- Randomized phase 3 ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens, **ESMO Annual Meeting (2019)**.
- Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer. **ASCO-SITC Clinical Immuno-Oncology Symposium (2019)**.
- Synergistic tumor-suppressive effect of apatinib, a selective VEGFR-2 inhibitor, in combination with immunotherapy in a syngeneic murine lung cancer model. **American Association for Cancer Research (AACR) Annual Meeting (2018)**.
- A Phase I study evaluating the pharmacokinetics of rivoceranib (apatinib) in healthy Caucasian, Japanese, and Chinese subjects. **American College of Clinical Pharmacology (2017)**.
- A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC)

South San Francisco U.S.

400 Oyster Point
Blvd, Suite 214
South San Francisco,
CA 94080
U.S.A.

Salt Lake City U.S. [Headquarters]

2825 E Cottonwood
Pkwy Suite 180,
Salt Lake City, UT
84121
U.S.A.

Phone: 801-303-7440
Fax: 801-303-7455

South Korea

7F Mayple Tower,
Teheran-ro 420,
Gangnam-gu, Seoul
06193
Republic of Korea

Ireland

The Black Church,
St Mary's Place,
Dublin, D07 P4AX,
Ireland

Phone: 353-1-969-6739
Fax: 353-1-685-3040